Relapse of TEL-AML1-positive acute lymphoblastic leukemia in childhood: A matched-pair analysis

Journal of Clinical Oncology

Volumn 19, Issue 13, 2001, Pages 3188-3193

  Seeger, K ^a   Stackelberg, A V ^a   Taube, T ^a   Buchwald, D ^a   Korner G ^a   Suttorp, M ^a   Dorffel W ^a   Tausch, W ^a   Henze, G ^a  

^a HUMBOLDT UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; PROTEIN; TEL AML1 PROTEIN; UNCLASSIFIED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ARTICLE; CANCER RECURRENCE; CANCER RISK; CANCER SURVIVAL; CHILD; CHROMOSOME TRANSLOCATION 12; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENE FUSION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; STATISTICAL ANALYSIS;

EID: 0035399173     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2001.19.13.3188     Document Type: Article

References (37)

1. Fifty years of studies of the biology and therapy of childhood leukemia
2. Recent advances in the biology and treatment of childhood acute lymphoblastic leukemia
3. Chemotherapy for relapsed childhood acute lymphoblastic leukemia: Results of the BFM Study Group
4. Relapsed lymphoblastic leukaemia in children: A continuing challenge
5. Clinical features and outcome of children with first marrow relapse of acute lymphoblastic leukemia expressing BCR-ABL fusion transcripts: BFM Relapse Study Group
6. TEL-AML1 fusion transcript in relapsed childhood acute lymphoblastic leukemia: The Berlin-Frankfurt-Munster Study Group
7. Philadelphia chromosome in relapsed childhood acute lymphoblastic leukemia: A matched-pair analysis - Berlin-Frankfurt-Munster Study Group
8. TEL gene rearrangement in acute lymphoblastic leukemia: A new genetic marker with prognostic significance
9. TEL/AML1 fusion resulting from a cryptic t(12;21) is the most common genetic lesion in pediatric ALL and defines a subgroup of patients with an excellent prognosis
10. TEL/AML-1 dimerizes and is associated with a favorable outcome in childhood acute lymphoblastic leukemia
11. Incidence and clinical relevance of TEL/AML1 fusion genes in children with acute lymphoblastic leukemia enrolled in the German and Italian multicenter therapy trials: Associazione Italiana Ematologia Oncologia Pediatrica and the Berlin-Frankfurt-Munster Study Group
12. TEL-AML1 positivity in relapsed B cell precursor acute lymphoblastic leukemia in childhood
13. TEL-AML1 fusion in relapsed childhood acute lymphoblastic leukemia
14. Incidence of TEL/AML1 fusion gene analyzed consecutively in children with acute lymphoblastic leukemia in relapse
15. Incidence of TEL/AML1 fusion in children with relapsed acute lymphoblastic leukemia
16. Low frequency of TEL-AML1 in relapsed acute lymphoblastic leukemia supports a favorable prognosis for this genetic subgroup
17. Peripheral blast counts at diagnosis of late isolated bone marrow relapse of childhood acute lymphoblastic leukemia predict response to salvage chemotherapy and outcome
18. Fusion of the TEL gene on 12p13 to the AML1 gene on 21q22 in acute lymphoblastic leukemia
19. The TEL/ETV6 gene is required specifically for hematopoiesis in the bone marrow
20. The t(12;21) translocation converts AML-1B from an activator to a repressor of transcription
21. AML1, the target of multiple chromosomal translocations in human leukemia, is essential for normal fetal liver hematopoiesis
22. Exogenous cdk4 overcomes reduced cdk4 RNA and inhibition of G1 progression in hematopoietic cells expressing a dominant-negative CBF: A model for overcoming inhibition of proliferation by CBF oncoproteins
23. The role of chromosome translocations in leukemogenesis
24. Recent advances in the biology and treatment of childhood acute lymphoblastic leukemia
25. The role of TEL fusion genes in pediatric leukemias
26. The core binding factor (CBF) alpha interaction domain and the smooth muscle myosin heavy chain (SMMHC) segment of CBFbeta-SMMHC are both required to slow cell proliferation
27. The chimeric genes AML1/MDS1 and AML1/EAP inhibit AML1B activation at the CSF1R promoter, but only AML1/MDS1 has tumor-promoter properties
28. Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia
29. Three distinct domains in TEL-AML1 are required for transcriptional repression of the IL-3 promoter
30. The ets family member Tel binds to the Fli-1 oncoprotein and inhibits its transcriptional activity
31. Occurrence of TEL-AML1 fusion resulting from (12;21) translocation in human early B-lineage leukemia cell lines
32. TEL-AML1 fusion transcript designates a favorable outcome with an intensified protocol in childhood acute lymphoblastic leukemia
33. Prognostic significance of TEL/AML1 fusion transcript in childhood B-precursor acute lymphoblastic leukemia
34. TEL/AML1 gene fusion is related to in vitro drug sensitivity for L-asparaginase in childhood acute lymphoblastic leukemia
35. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia
36. Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood